Diagnostic value of plasma lysophosphatidic acid levels in ovarian cancer patients: A case-control study and updated meta-analysis

Journal of Obstetrics and Gynaecology Research

Volumn 41, Issue 12, 2015, Pages 1951-1958

  Cao, Liyan ^a   Zhang, Yunjie ^a   Fu, Zhanzhao ^a   Dong, Lixin ^a   Yang, Sen ^a   Meng, Wei ^b   Li, Yiyang ^a   Zhang, Wenchao ^a   Zhang, Jialing ^a   Zheng, Changjun ^a   Zhu, He ^a   Fan, Limei ^a  

^a Radiation Oncology Division   (China)

^b HEBEI NORTH UNIVERSITY   (China)

Author keywords

bioactive phospholipid; differential diagnosis; lysophosphatidic acid; ovarian cancer; sensitivity and specificity

Indexed keywords

CA 125 ANTIGEN; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHOLIPID;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PHOSPHOLIPID BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; BLOOD; CASE CONTROL STUDY; META ANALYSIS; MIDDLE AGED; OVARIAN NEOPLASMS; RECEIVER OPERATING CHARACTERISTIC;

ADULT; AGED; CA-125 ANTIGEN; CASE-CONTROL STUDIES; FEMALE; HUMANS; LYSOPHOSPHOLIPIDS; MIDDLE AGED; OVARIAN NEOPLASMS; ROC CURVE;

EID: 84962010496     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/jog.12806     Document Type: Article

References (52)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics. CA Cancer J Clin 2013; 63: 11-30.
2. Chornokur G, Amankwah EK, Schildkraut JM, Phelan CM,. Global ovarian cancer health disparities. Gynecol Oncol 2013; 129: 258-264.
3. Yang L, Parkin DM, Ferlay J, Li L, Chen Y,. Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev 2005; 14: 243-250.
4. Kim K, Zang R, Choi SC, Ryu SY, Kim JW,. Current status of gynecological cancer in China. J Gynecol Oncol 2009; 20: 72-76.
5. Lowe KA, Chia VM, Taylor A, et al., An international assessment of ovarian cancer incidence and mortality. Gynecol Oncol 2013; 130: 107-114.
6. Chiang YC, Chen CA, Chiang CJ, et al., Trends in incidence and survival outcome of epithelial ovarian cancer: 30-year national population-based registry in Taiwan. J Gynecol Oncol 2013; 24: 342-351.
7. Rossing MA, Wicklund KG, Cushing-Haugen KL, Weiss NS,. Predictive value of symptoms for early detection of ovarian cancer. J Natl Cancer Inst 2010; 102: 222-229.
8. Jayson GC, Kohn EC, Kitchener HC, Ledermann JA,. Ovarian cancer. Lancet 2014; 384: 1376-1388.
9. Bast RC Jr,. Status of tumor markers in ovarian cancer screening. J Clin Oncol 2003; 21: 200s-205s.
10. Lutz AM, Willmann JK, Drescher CW, et al., Early diagnosis of ovarian carcinoma: Is a solution in sight? Radiology 2011; 259: 329-345.
11. Yurkovetsky ZR, Linkov FY, Malehorn DE, Lokshin AE,. Multiple biomarker panels for early detection of ovarian cancer. Future Oncol 2006; 2: 733-741.
12. Gentry-Maharaj A, Menon U,. Screening for ovarian cancer in the general population. Best Pract Res Clin Obstet Gynaecol 2012; 26: 243-256.
13. Yin BW, Lloyd KO,. Molecular cloning of the CA125 ovarian cancer antigen: Identification as a new mucin, MUC16. J Biol Chem 2001; 276: 27371-27375.
14. Theriault C, Pinard M, Comamala M, et al., MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis. Gynecol Oncol 2011; 121: 434-443.
15. Giannakouros P, Comamala M, Matte I, Rancourt C, Piche A,. MUC16 mucin (CA125) regulates the formation of multicellular aggregates by altering beta-catenin signaling. Am J Cancer Res 2015; 5: 219-230.
16. Moss EL, Hollingworth J, Reynolds TM,. The role of CA125 in clinical practice. J Clin Pathol 2005; 58: 308-312.
17. Eder AM, Sasagawa T, Mao M, Aoki J, Mills GB,. Constitutive and lysophosphatidic acid (LPA)-induced LPA production: Role of phospholipase D and phospholipase A2. Clin Cancer Res 2000; 6: 2482-2491.
18. Mills GB, Eder A, Fang X, et al., Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer. Cancer Treat Res 2002; 107: 259-283.
19. Mills GB, Moolenaar WH,. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 2003; 3: 582-591.
20. Ren J, Xiao YJ, Singh LS, et al., Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells. Cancer Res 2006; 66: 3006-3014.
21. Sedlakova I, Vavrova J, Tosner J, Hanousek L,. Lysophosphatidic acid (LPA): A perspective marker in ovarian cancer. Tumour Biol 2011; 32: 311-316.
22. Chen H, Wu X, Pan ZK, Huang S,. Integrity of SOS1/EPS8/ABI1 tri-complex determines ovarian cancer metastasis. Cancer Res 2010; 70: 9979-9990.
23. Pozlep B, Meleh M, Kobal B, et al., Use of lysophosphatidic acid in the management of benign and malignant ovarian tumors. Eur J Gynaecol Oncol 2007; 28: 394-399.
24. Glas J, Seiderer J, Bues S, et al., IRGM variants and susceptibility to inflammatory bowel disease in the German population. PLoS One 2013; 8: e54338.
25. Pereira A, Perez-Medina T, Magrina JF, et al., International Federation of Gynecology and Obstetrics staging classification for cancer of the ovary, fallopian tube, and peritoneum: Estimation of survival in patients with node-positive epithelial ovarian cancer. Int J Gynecol Cancer 2015; 25: 49-54.
26. Hu YL, Tee MK, Goetzl EJ, et al., Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Inst 2001; 93: 762-768.
27. Bese T, Barbaros M, Baykara E, et al., Comparison of total plasma lysophosphatidic acid and serum CA-125 as a tumor marker in the diagnosis and follow-up of patients with epithelial ovarian cancer. J Gynecol Oncol 2010; 21: 248-254.
28. Chen H, Manning AK, Dupuis J,. A method of moments estimator for random effect multivariate meta-analysis. Biometrics 2012; 68: 1278-1284.
29. Jackson D, White IR, Riley RD,. Quantifying the impact of between-study heterogeneity in multivariate meta-analyses. Stat Med 2012; 31: 3805-3820.
30. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L,. Comparison of two methods to detect publication bias in meta-analysis. JAMA 2006; 295: 676-680.
31. Zintzaras E, Ioannidis JP,. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 2005; 28: 123-137.
32. Cao XY,. The applicable value of combined detection of LPA, CA1 25 and AFP in the early diagnosis of ovarian cancer. Lab Med Clin 2008; 5: 1430-1431.
33. Chen YN, Tao M, Tu FP, Zuo Y, Lu WD,. LPA, IL-6 and IL-8 levels in the plasma of patients with epithelial ovarian carcinoma. Pract J Cancer 2008; 23: 580-582.
34. Ding F, Niu B,. Clinical significance of detecting lysophosphatidic acid and vascular endothelial growth factor in patients with epithelial ovarian carcinoma. Pract J Med Pharm 2013; 30: 775-777.
35. Du Y,. Study on correlation between diagnosis of epithelial ovarian cancer and plasma lysophosphatidic acid. Zhejiang Med J 2005; 27: 827-828.
36. Duan ML, Wu F,. The diagnostic value of secretory phospholipase A2 and lysophosphatic acid for ovarian cancer. Chin J Lab Med 2005; 28: 622-624.
37. Guo HY, Han JS, Wu QZ, Yang CS,. A study of diagnostic value of plasma lysophosphatidic acid for ovarian epithelial cancer. Chin J Clin Obstet Gynecol 2002; 3: 36-38.
38. Lao M, Pan ZM, Huang WC, et al., The value of plasma lysophosphatidic acid measurement in the diagnosis of gynecology tumor. Pract J Cancer 2007; 22: 347-349.
39. Li C, Fang SH, Chen W,. The diagnostic value of soluble P185 in ovarian cancer. Chin J Lab Diagn 2007; 11: 1238-1239.
40. Lian XF, Li XL, Zhan HL, Sun F,. The diagnostic value when lysophospholipids acid, epididymis protein 4 used in early ovarian cancer' s detection. Inter Med Health Guid News 2010; 16: 2778-2781.
41. Liang HF, Zhang H, Ma XY,. Comparative analysis of the value of lysophosphatidic acid and CA125 in the diagnosis of ovarian cancer. Clin Med Chin 2011; 27: 348-350.
42. Liao JR, Zong JH, Lv YY,. Detection of plasma lysophosphatidic acid (LPA) in epithelial ovarian tumor patients. Inner Mongolia Med J 2010; 42: 1295-1296.
43. Wang DL, Chen LX, Liao XL, Liao XJ, Wu QH,. The relationship of lysophosphatidic acid and MMP-2 in diagnosing epithelial ovarian carcinoma. Proc Clin Med 2013; 22: 403-405.
44. Wang H, Chen DZ,. Study on the diagnostic value of plasma lysophosphatidic acid (LPA) level determination in patients with ovarian carcinoma. J Radioimmunol 2008; 21: 355-357.
45. Yan ZT, Huang N, Zhao ML, Pang AP,. Clinical values of serum CA125 and LPA determination in early diagnosis of ovarian cancer. Chin J Prim Med Phar 2009; 16: 1993-1994.
46. Zhang YM, Zhang XN,. Expression of XIAP, Survivin, LPA and CA12 5 in human epithelial ovarian carcinoma. J Shandong Univ (Health Science) 2007; 45: 317-321.
47. Murph M, Tanaka T, Pang J, et al., Liquid chromatography mass spectrometry for quantifying plasma lysophospholipids: Potential biomarkers for cancer diagnosis. Methods Enzymol 2007; 433: 1-25.
48. Xu Y, Shen Z, Wiper DW, et al., Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 1998; 280: 719-723.
49. Nossov V, Amneus M, Su F, et al., The early detection of ovarian cancer: From traditional methods to proteomics. Can we really do better than serum CA-125? Am J Obstet Gynecol 2008; 199: 215-223.
50. Baron JA,. Screening for cancer with molecular markers: Progress comes with potential problems. Nat Rev Cancer 2012; 12: 368-371.
51. Goldsmith ZG, Ha JH, Jayaraman M, Dhanasekaran DN,. Lysophosphatidic acid stimulates the proliferation of ovarian cancer cells via the gep proto-oncogene Gα(12). Genes Cancer 2011; 2: 563-575.
52. Dutta S, Wang FQ, Wu HS, Mukherjee TJ, Fishman DA,. The NF-κB pathway mediates lysophosphatidic acid (LPA)-induced VEGF signaling and cell invasion in epithelial ovarian cancer (EOC). Gynecol Oncol 2011; 123: 129-137.